The rare cancer network: ongoing studies and future strategy.

Area of Science:

• Oncology
• Rare Diseases
• Clinical Research Networks

Background:

• The Rare Cancer Network (RCN) was established in the early 1990s to address the challenges of studying rare malignancies.
• Its mission is to pool global knowledge and resources, overcoming the limitations posed by the infrequency of these cancers for prospective clinical trials.

Observation:

• The RCN has initiated 74 studies, resulting in 46 peer-reviewed publications.
• The First International Symposium of the RCN in March 2014 convened to discuss ongoing studies and new proposals for fifteen rare cancer topics.
• Updates were provided on cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas.

Findings:

• New study proposals were presented for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, ampullary tumors, salivary gland tumors, anorectal melanoma, testicular carcinoma, pulmonary lymphoepithelioma-like carcinoma, tracheal adenoid cystic carcinoma, mandibular osteosarcomas, and extra-cranial hemangiopericytoma.
• The manuscript details abstracts of these new proposals and updates on ongoing research.

Implications:

• The RCN's collaborative model enhances the study of rare cancers, driving research and publication output.
• The network's ongoing expansion of study topics signifies a growing commitment to rare malignancy research.
• This work highlights the RCN's vision and future direction in advancing rare cancer understanding and treatment.